Investor Presentaiton

31 MEUR Net sales bridge from FY2022 to FY2023 1,340.6 -33.0 95.4 -25.0 -32.3 58.1 10.0 ORION 1,189.7 -201.2 -23.1 8 2023 2022 1 2 3 4 5 6 7 1 Simdax® and dexmedetomidine for human use 5 Other products and services (excl. Animal Health and Fermion) 2 Nubeqa (product sales and royalty) 6 Animal Health and Fermion 3 Entacapone products 7 Milestones 4 Russia 8 Exchange rates Investor Presentation Orion Corporation The figures in the chart are rounded, which is why the total sums of individual figures may differ from the total sums.

View entire presentation